Erste Group Bank Has Negative Outlook of ABT FY2027 Earnings

Key Points

• Erste Group Bank slightly lowered its FY2027 earnings estimate for Abbott Laboratories to $6.04 per share from $6.05, though that is still above the current consensus estimate of $5.48.
• Abbott’s most recent quarterly results were solid, with EPS of $1.15 and revenue of $11.16 billion, both modestly ahead of Wall Street expectations. The company also guided FY2026 EPS to $5.38-$5.58.
• Analysts remain mostly constructive on the stock despite recent target cuts: the consensus rating is Moderate Buy with an average price target of $119.09, while ABT shares were down about 2.3% and trading well below their 200-day average.

Abbott Laboratories (NYSE:ABT - Free Report) - Analysts at Erste Group Bank cut their FY2027 earnings estimates for Abbott Laboratories in a research report issued on Friday, June 5th. Erste Group Bank analyst H. Engel now anticipates that the healthcare product maker will post earnings of $6.04 per share for the year, down from their prior estimate of $6.05. The consensus estimate for Abbott Laboratories' current full-year earnings is $5.48 per share.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion for the quarter, compared to analysts' expectations of $10.99 billion. During the same period in the previous year, the company posted $1.09 earnings per share. The business's revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS.

Other analysts have also issued research reports about the stock. Oppenheimer dropped their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. Weiss Ratings lowered shares of Abbott Laboratories from a "hold (c)" rating to a "hold (c-)" rating in a research note on Friday, April 24th. Raymond James Financial dropped their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. Argus dropped their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating for the company in a research note on Tuesday, April 21st. Finally, Citigroup dropped their price target on shares of Abbott Laboratories from $136.00 to $108.00 and set a "buy" rating for the company in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $119.09.

Abbott Laboratories Stock Down 2.3%

Shares of NYSE:ABT opened at $89.15 on Thursday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a fifty day simple moving average of $92.01 and a 200 day simple moving average of $108.39. The firm has a market cap of $155.29 billion, a PE ratio of 24.97, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06.

Institutional Trading of Abbott Laboratories

A number of institutional investors and hedge funds have recently modified their holdings of the business. Freemont Management S.A. grew its position in shares of Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock worth $1,341,000 after acquiring an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab bought a new position in shares of Abbott Laboratories during the fourth quarter worth about $116,580,000. Thrivent Financial for Lutherans grew its position in shares of Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock worth $30,931,000 after acquiring an additional 48,286 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new position in shares of Abbott Laboratories during the third quarter worth about $185,640,000. Finally, Net Worth Advisory Group bought a new position in shares of Abbott Laboratories during the fourth quarter worth about $1,366,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of the company's stock in a transaction on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares of the company's stock, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the company's stock in a transaction on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares of the company's stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by corporate insiders.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott continues to gain attention for its cancer diagnostics growth story, with the Exact Sciences acquisition expanding its diagnostics portfolio and supportive screening data improving the long-term outlook. Mounting Evidence Backs Abbott's Cancer Diagnostics Growth Story
• Positive Sentiment: Abbott also received a boost from news that it secured CE Mark for its Libre Duo dual glucose-ketone sensing technology, a potential growth driver in diabetes care. Abbott (ABT) Secures CE Mark for World’s First Dual Glucose-Ketone Sensing Technology for Diabetes
• Neutral Sentiment: ABT is being highlighted as a trending stock across financial media, suggesting rising investor interest but not necessarily a clear catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analyst commentary also noted Abbott as a blue-chip, defensive name for long-term portfolios, reinforcing its stability and dividend appeal rather than signaling a near-term earnings surprise. New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around
• Negative Sentiment: Despite the positive business updates, the stock has still been trading lower, reflecting broader selling pressure and investor caution after recent gains. Abbott (ABT) Dips More Than Broader Market: What You Should Know

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.